Table 1.
Demographical characteristics, body composition, and renal parameters of patients assigned to add-on treatment with eplerenone (50 mg/day) and standard hypertensive treatment before (V1) and after 6 months (V2). All values are reported as median (interquartile range). The statistical comparison of parameters before (V1) and after treatment (V2) was conducted with Wilcoxon test (WLCXN) while the Eplerenone versus standard hypertensive treatment before comparison was conducted with Mann–Whitney U test (MW-U) except Pearson’s chi-squared test (χ2) for gender.
| Parameter | Add-on Therapy—with Eplerenone | Standard Antihypertensive Therapy | ||
|---|---|---|---|---|
| Gender (n/%) | V1 | p > 0.05 | ||
| M | 29 | 30 | ||
| F | 22 | 21 | ||
| Age (years) | V1 | 59.0 (52.0–62.0) | 59.0 (52.0–62.0) | p > 0.05 |
| Height (cm) | V1 | 1.7 (1.64–1.75) | 1.7 (1.65–1.76) | p > 0.05 |
| Weight (kg) |
V1 | 102.3 (88.7–112.4) | 102.3 (90.3–111.2) | p > 0.05 |
| V2 | 101.2 (87.7–111.9) | 101.3 (83.4–116.9) | p > 0.05 | |
| WLCXN | p < 0.001 | p > 0.05 | ||
| Body mass index (kg/m2) |
V1 | 36.1 (33.0–37.6) | 35.4 (32.1–37.4) | p > 0.05 |
| V2 | 35.6 (32.3–37.2) | 35.3 (30.3–39.1) | p > 0.05 | |
| WLCXN | p < 0.001 | p > 0.05 | ||
| Neck (cm) |
V1 | 43.0 (40.0–47.0) | 44.0 (39.0–46.0) | p > 0.05 |
| V2 | 42.0 (39.0–44.0) | 44.0 (34.0–47.0) | p > 0.05 | |
| WLCXN | p < 0.001 | p > 0.05 | ||
| Waist (cm) |
V1 | 105.0 (98.0–118.0) | 104.0 (98.0–116.0) | p > 0.05 |
| V2 | 104.0 (99.0–116.0) | 103.0 (87.0–121.0) | p > 0.05 | |
| WLCXN | p < 0.001 | p > 0.05 | ||
| Serum potassium (mmol/L) |
V1 | 4.1 (3.9–4.3) | 4.1 (3.8–4.6) | p > 0.05 |
| V2 | 4.4 (4.2–4.6) | 4.1 (3.5–4.6) | p > 0.001 | |
| WLCXN | p < 0.001 | p > 0.05 | ||
| Serum creatinine (µmol/L) |
V1 | 82.4 (73.4–90.9) | 80.1 (74.6–89.3) | p > 0.05 |
| V2 | 85.7 (77.5–92.4) | 80.9 (74.3–91.3) | p > 0.05 | |
| WLCXN | p < 0.01 | p < 0.05 | ||
| Glomerular filtration rate (mL/min) |
V1 | 85.0 (62.0–99.0) | 81.0 (63.0–96.0) | p > 0.05 |
| V2 | 80.0 (62.0–96.0) | 80.0 (63.0–96.0) | p > 0.05 | |
| WLCXN | p < 0.01 | p < 0.05 | ||
| Plasma renin activity (ng/mL/h) |
V1 | 0.2 (0.2–1.3) | 1.0 (0.2–1.2) | p < 0.01 |
| V2 | 1.3 (1.1–2.1) | 1.2 (0.2–1.8) | p < 0.001 | |
| WLCXN | p < 0.001 | p < 0.05 | ||
| Plasma aldosterone (ng/dL) |
V1 | 10.1 (6.5–12.9) | 10.3 (7.4–11.3) | p > 0.05 |
| V2 | 5.5 (3.5–7.3) | 10.2 (5.7–13.5) | p < 0.001 | |
| WLCXN | p < 0.001 | p > 0.05 | ||
| Aldosterone–renin ratio | V1 | 4.8 (0.4–8.6) | 1.0 (0.7–5.3) | p > 0.05 |
| V2 | 0.4 (0.2–0.6) | 0.9 (0.5–5.2) | p < 0.001 | |
| p < 0.001 | p < 0.05 |